{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:04:32Z","timestamp":1785434672971,"version":"3.56.0"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004504","name":"Research Council of Lithuania","doi-asserted-by":"publisher","award":["S-MIP-23-100"],"award-info":[{"award-number":["S-MIP-23-100"]}],"id":[{"id":"10.13039\/501100004504","id-type":"DOI","asserted-by":"publisher"}]},{"award":["S-MIP-23-100"],"award-info":[{"award-number":["S-MIP-23-100"]}],"id":[{"id":"https:\/\/ror.org\/02gs16m83","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Microscopic colitis (MC) encompasses two chronic inflammatory disorders of the large intestine: collagenous colitis (CC) and lymphocytic colitis (LC). Both conditions are characterised by chronic watery diarrhoea and substantially impaired quality of life. Diagnosis relies on colonoscopy with multiple biopsies, and no reliable non-invasive biomarker currently exists. This exploratory study aimed to investigate circulating fatty acid-binding protein 2 (FABP2), interleukin-10 (IL-10), and lipopolysaccharides (LPSs) as potential biomarkers for MC and to compare their profiles with those in ulcerative colitis (UC). Materials and Methods: Plasma samples were obtained from 45 patients with active CC, 16 patients with active LC, 52 healthy controls, 43 patients with active UC, and 43 patients with inactive UC. Concentrations of FABP2, IL-10, and LPS were measured by enzyme-linked immunosorbent assay (ELISA). Results: Plasma FABP2 concentrations differed significantly across groups (Kruskal\u2013Wallis p = 0.008). CC patients exhibited the highest levels (median 1719.0 pg\/mL, IQR 1364.0\u20132240.0) compared with active UC (median 1272.0 pg\/mL, IQR 861.7\u20131727.5; p = 0.005) and inactive UC (median 1334.0 pg\/mL, IQR 854.2\u20131702.0; p = 0.001), but did not differ significantly from controls (median 1364.5 pg\/mL, IQR 982.6\u20132160.5; p = 0.076) or LC (median 1421.5 pg\/mL, IQR 1207.0\u20132002.2; p = 0.171). IL-10 concentrations also differed across groups (Kruskal\u2013Wallis p = 0.029 after removal of one extreme outlier in active UC). Active UC patients had significantly lower levels (median 2.6 pg\/mL, IQR 1.4\u20134.6) than CC (median 4.0 pg\/mL, IQR 3.0\u20137.2; p = 0.009) and controls (median 4.8 pg\/mL, IQR 2.6\u20137.4; p = 0.005). LPS concentrations showed no overall differences across groups (Kruskal\u2013Wallis p = 0.55), although CC patients had numerically higher levels (median 73.7 pg\/mL, IQR 45.6\u2013104.9) compared with controls (median 56.4 pg\/mL, IQR 33.7\u201387.1; p = 0.124). No significant differences were observed between LC and other groups for any biomarker. Conclusions: In this exploratory study, plasma FABP2 and IL-10 showed limited diagnostic accuracy in differentiating CC from UC but failed to distinguish MC from healthy controls. LPS levels were not significantly different among study groups. None of the biomarkers reliably separated LC from other groups, possibly reflecting the small LC sample size. These preliminary findings suggest subtle differences in circulating biomarker profiles between CC and UC that warrant validation in larger cohorts.<\/jats:p>","DOI":"10.3390\/medicina62071237","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:43:57Z","timestamp":1782463437000},"page":"1237","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma FABP2, IL-10, and LPS in Microscopic Colitis: An Exploratory Study of Their Biomarker Potential"],"prefix":"10.3390","volume":"62","author":[{"given":"Vytautas","family":"Kiudelis","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania"},{"name":"Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu St. 4, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Gedgaudien\u0117","sequence":"additional","affiliation":[{"name":"Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu St. 4, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justina","family":"Veli\u010dkien\u0117","sequence":"additional","affiliation":[{"name":"Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu St. 4, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalius","family":"Petrauskas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgita","family":"Skiecevi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu St. 4, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-7416","authenticated-orcid":false,"given":"Juozas","family":"Kup\u010dinskas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania"},{"name":"Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu St. 4, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gediminas","family":"Kiudelis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania"},{"name":"Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu St. 4, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-3675","authenticated-orcid":false,"given":"Laimas Virginijus","family":"Jonaitis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania"},{"name":"Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu St. 4, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2050640620951905","article-title":"European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations","volume":"9","author":"Miehlke","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.dld.2010.06.004","article-title":"Health-related quality of life is impaired in active collagenous colitis","volume":"43","author":"Hjortswang","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/apt.12685","article-title":"Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: A case\u2013control study","volume":"39","author":"Nyhlin","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/gast.2002.30295","article-title":"Budesonide in collagenous colitis: A double-blind placebo-controlled trial with histologic follow-up","volume":"122","author":"Baert","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gutjnl-2014-308363","article-title":"Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomised, placebo-controlled, 12-month trial","volume":"65","author":"Bohr","year":"2016","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/gut.52.2.248","article-title":"Budesonide treatment of collagenous colitis: A randomised, double blind, placebo controlled trial with morphometric analysis","volume":"52","author":"Bonderup","year":"2003","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/gast.2002.36042","article-title":"Budesonide treatment for collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial","volume":"123","author":"Miehlke","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1053\/j.gastro.2014.01.019","article-title":"Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis","volume":"146","author":"Miehlke","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/gut.2008.156513","article-title":"Long-term budesonide treatment of collagenous colitis: A randomised, double-blind, placebo-controlled trial","volume":"58","author":"Bonderup","year":"2008","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1053\/j.gastro.2018.08.042","article-title":"Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis","volume":"155","author":"Miehlke","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ecco-jcc\/jjab007","article-title":"Course of Disease in Patients with Microscopic Colitis: A European Prospective Incident Cohort Study","volume":"15","author":"Verhaegh","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10753-013-9612-4","article-title":"Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis","volume":"36","author":"Wagner","year":"2013","journal-title":"Inflammation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/00365521.2016.1141432","article-title":"Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea","volume":"51","author":"Wagner","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0009-9120(03)00096-1","article-title":"Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility","volume":"36","author":"Pelsers","year":"2003","journal-title":"Clin. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12519-015-0035-1","article-title":"Clinical significance of FABP2 expression in newborns with necrotizing enterocolitis","volume":"12","author":"Liu","year":"2015","journal-title":"World J. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.12194","article-title":"Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies","volume":"37","author":"Adriaanse","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7754\/Clin.Lab.2014.140518","article-title":"Intestinal Fatty Acid Binding Protein (I-FABP) as a Promising Test for Crohn\u2019s Disease: A Preliminary Study","volume":"61","author":"Sarikaya","year":"2015","journal-title":"Clin. Lab."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Logan, M., MacKinder, M., Clark, C.M., Kountouri, A., Jere, M., Ijaz, U.Z., Hansen, R., McGrogan, P., Russell, R.K., and Gerasimidis, K. (2022). Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn\u2019s disease. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02334-6"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/MEG.0000000000000616","article-title":"Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients","volume":"28","author":"Bodelier","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"i202","DOI":"10.1093\/ecco-jcc\/jjab232.239","article-title":"P111 Gut barrier markers in Inflammatory Bowel Disease","volume":"16","author":"Nguyen","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1136\/gutjnl-2024-334604","article-title":"Enterococcus faecalis hijacks FABP2 to activate quorum-sensing signals and aggravate Crohn\u2019s disease by inducing gut dysbiosis","volume":"74","author":"Sun","year":"2025","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.3748\/wjg.v20.i12.3255","article-title":"Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease","volume":"20","author":"Xu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"26875","DOI":"10.1155\/MI\/2006\/26875","article-title":"Interleukin-10 in the pathophysiology of inflammatory bowel disease: Increased serum concentrations during the recovery phase","volume":"2006","author":"Mitsuyama","year":"2006","journal-title":"Mediat. Inflamm."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Godala, M., Gaszy\u0144ska, E., Walczak, K., and Ma\u0142ecka-Wojciesko, E. (2023). Role of Serum Interleukin-6, Interleukin-1\u03b2 and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185956"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1002\/iid3.710","article-title":"Mucosal Interleukin-10 depletion in steroid-refractory Crohn\u2019s disease patients","volume":"10","author":"Carrasco","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/ecco-jcc\/jjw058","article-title":"Immunological Differences between Lymphocytic and Collagenous Colitis","volume":"10","author":"Carrasco","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"bvz039","DOI":"10.1210\/jendso\/bvz039","article-title":"Intestinal barrier dysfunction, LPS translocation, and disease development","volume":"4","author":"Ghosh","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5217\/ir.2017.15.3.352","article-title":"Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn\u2019s disease","volume":"15","author":"Magro","year":"2017","journal-title":"Intest. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"843089","DOI":"10.1155\/2015\/843089","article-title":"Serum Levels of Lipopolysaccharide and 1,3-\u03b2-D-Glucan Refer to the Severity in Patients with Crohn\u2019s Disease","volume":"2015","author":"Guo","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ibd.20019","article-title":"Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease","volume":"13","author":"Rojo","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/imm.12114","article-title":"Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation","volume":"140","author":"Funderburg","year":"2013","journal-title":"Immunology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/gut.2004.058750","article-title":"Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy","volume":"54","author":"Wallon","year":"2005","journal-title":"Gut"},{"key":"ref_33","first-page":"679","article-title":"Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment","volume":"104","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s00535-017-1309-2","article-title":"Epithelial barrier dysfunction in lymphocytic colitis through cytokine-dependent internalization of claudin-5 and -8","volume":"52","author":"Barmeyer","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ibd.20977","article-title":"Defining clinical criteria for clinical remission and disease activity in collagenous colitis","volume":"15","author":"Hjortswang","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pisani, L.F., Tontini, G.E., Marinoni, B., Villanacci, V., Bruni, B., Vecchi, M., and Pastorelli, L. (2017). Biomarkers and Microscopic Colitis: An Unmet Need in Clinical Practice. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00054"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s12098-016-2144-9","article-title":"Diagnostic Value of Intestinal Fatty-Acid-Binding Protein in Necrotizing Enterocolitis: A Systematic Review and Meta-Analysis","volume":"83","author":"Yang","year":"2016","journal-title":"Indian J. Pediatr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/bjs.9331","article-title":"Diagnostic performance of plasma biomarkers in patients with acute intestinal ischaemia","volume":"101","author":"Matsumoto","year":"2014","journal-title":"Br. J. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.regpep.2007.12.002","article-title":"Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis","volume":"147","author":"Jaroszewicz","year":"2008","journal-title":"Regul. Pept."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41572-021-00273-2","article-title":"Microscopic colitis","volume":"7","author":"Burke","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.cgh.2018.03.002","article-title":"Associations of Microscopic Colitis with Other Lymphocytic Disorders of the Gastrointestinal Tract","volume":"16","author":"Sonnenberg","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11882-012-0286-z","article-title":"Interleukin-10 and Interleukin-10\u2013Receptor Defects in Inflammatory Bowel Disease","volume":"12","author":"Shah","year":"2012","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Roth, B., Gustafsson, R.J., and Ohlsson, B. (2013). Auto-Antibodies and Their Association with Clinical Findings in Women Diagnosed with Microscopic Colitis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066088"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Candelli, M., Franza, L., Pignataro, G., Ojetti, V., Covino, M., Piccioni, A., Gasbarrini, A., and Franceschi, F. (2021). Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126242"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1237\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:38:38Z","timestamp":1782470318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071237"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071237","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}